CDK4/6 Inhibitors in Breast Cancer: An Oncology Nurse’s Toolkit to Enhance Tolerability and Preserve Benefit

Achieve a greater understanding of the toxicities associated with CDK4/6 inhibitor therapy in HR+/HER2- breast cancer to effectively monitor and manage adverse events as well as strategies that can be implemented to increase adherence through an on-demand webcast, downloadable slides and accompanying resource, and expert-written ClinicalThought commentary.

Share

Program Content

Activities

CDK4/6i Pocket Guide for Nurses
Nursing Management of Patients Receiving CDK4/6 Inhibitor Therapy: A Pocket Guide
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: May 02, 2025

Expires: May 01, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation